

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability											Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
Set 1																								
(81) Digoxin	[μg/L]				130							0								130	128	98%		
Samples and groups																								
Sample A1		1,02	0,18	18	130							0		CRV	1,032	0,0100	36%	0,66	1,41	130	128	98%		
(1) Abbott		0,837	0,10	12	43	0																43		
(12) Beckman Coulter		1,12	0,12	10	12	0																12		
(58) Beckman Coulter (AU)		1,02	0,04	4,2	7	0																7		
(60) Roche		1,11	0,09	8,7	45	0																45		
(162) Siemens (Atellica)		1,11	0,13	12	10	0																10		
(179) Siemens		1,13	0,20	18	7	0																7		
Other					6	0																6		
														2x 29, 3x 149, 1x 166								6		
Sample B1		2,15	0,24	11	130							0		CRV	2,149	0,023	36%	1,37	2,93	130	129	99%		
(1) Abbott		1,91	0,22	12	43	0																43		
(12) Beckman Coulter		2,33	0,29	13	12	0																12		
(58) Beckman Coulter (AU)		2,21	0,11	5,0	7	0																7		
(60) Roche		2,22	0,11	4,9	45	0																45		
(162) Siemens (Atellica)		2,30	0,20	8,6	10	0																10		
(179) Siemens		2,41	0,22	8,9	7	0																7		
Other					6	0																6		
														2x 29, 3x 149, 1x 166								6		
(87) Ethosuximide	[mg/L]				6							6	6	100%								0		
Samples and groups																								
Sample A1		99,3	3,1	3,1	6		CVP	99,3	4,3	24%	75,4	124		6	6	100%						0		
Other					6	0								6								6		
							2x 118, 4x 999																	
Sample B1		27,5	2,0	7,1	6		CVP	27,5	2,7	24%	20,9	34,1		6	6	100%						0		
Other					6	0								6								6		
							2x 118, 4x 999																	
(84) Phenobarbital	[mg/L]				23									23	21	91%						0		
Samples and groups																								
Sample A1		25,3	2,3	9,1	23		CVP	25,3	1,2	20%	20,2	30,4		23	22	96%						0		
(1) Abbott		25,7	3,6	14	10	0								10										
(60) Roche		24,2	0,82	3,4	6	0								6										
Other					7	0								7										
							1x 58, 1x 118, 1x 162, 2x 179, 2x 999																	
Sample B1		9,08	0,82	9,1	23		CVP	9,08	0,42	20%	7,26	10,9		23	22	96%						0		
(1) Abbott		9,31	1,1	12	10	0								10										
(60) Roche		8,73	0,48	5,5	6	0								6										
Other					7	0								7										
							1x 58, 1x 118, 1x 162, 2x 179, 2x 999																	

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(85) Phenytoin						38						38	37	97%								0	
Samples and groups	[mg/L]																						
Sample A1		9,57	0,60	6,2	38	CVP	9,57	0,24	20%	7,65	11,5	38	37	97%								0	
(1) Abbott		9,38	1,0	11	12	0						12											
(60) Roche		9,77	0,48	4,9	13	0						13											
Other					13	0						13											
							3x 29, 3x 58, 1x 118, 2x 162, 1x 179, 3x 999																
Sample B1		3,95	0,34	8,7	38	CVP	3,95	0,14	20%	3,16	4,74	38	37	97%								0	
(1) Abbott		4,09	0,25	6,2	12	0						12											
(60) Roche		3,97	0,42	11	13	0						13											
Other					13	0						13											
							3x 29, 3x 58, 1x 118, 2x 162, 1x 179, 3x 999																
(86) Carbamazepin						60						60	54	90%								0	
Samples and groups	[mg/L]																						
Sample A1		10,1	0,87	8,6	60	CVP	10,1	0,27	20%	8,08	12,2	60	55	92%								0	
(1) Abbott		9,72	0,74	7,6	21	0						21											
(29) Siemens (Immolute)		9,31	0,50	5,4	5	0						5											
(60) Roche		10,6	0,70	6,6	17	0						17											
Other					17	0						17											
							1x 12, 4x 58, 2x 118, 2x 149, 2x 162, 3x 179, 3x 999																
Sample B1		3,43	0,34	9,8	60	CVP	3,43	0,11	20%	2,74	4,12	60	56	93%								0	
(1) Abbott		3,41	0,32	9,4	21	0						21											
(29) Siemens (Immolute)		3,28	0,14	4,3	5	0						5											
(60) Roche		3,47	0,29	8,3	17	0						17											
Other					17	0						17											
							1x 12, 4x 58, 2x 118, 2x 149, 2x 162, 3x 179, 3x 999																
(88) Valproic acid						84						84	80	95%								0	
Samples and groups	[mg/L]																						
Sample A1		35,3	3,1	8,9	84	CVP	35,3	0,84	20%	28,2	42,4	84	81	96%								0	
(1) Abbott		33,4	2,7	8,2	33	0						33											
(29) Siemens (Immolute)		37,2	3,8	10	6	0						6											
(58) Beckman Coulter (AU)		37,8	2,7	7,1	6	0						6											
(60) Roche		35,7	2,2	6,3	28	0						28											
Other					11	0						11											
							2x 12, 2x 149, 3x 162, 4x 179																
Sample B1		127	7,9	6,2	84	CVP	127	2,1	20%	101	153	84	83	99%								0	
(1) Abbott		124	7,4	6,0	33	0						33											
(29) Siemens (Immolute)		138	4,1	2,9	6	0						6											
(58) Beckman Coulter (AU)		135	5,9	4,4	6	0						6											
(60) Roche		126	4,7	3,8	28	0						28											
Other					11	0						11											
							2x 12, 2x 149, 3x 162, 4x 179																
(83) Primidone						8						8	8	100%								0	
Samples and groups	[mg/L]																						
Sample A1		9,94	0,83	8,4	8	CVP	9,94	0,63	24%	7,55	12,4	8	8	100%								0	
Other					8	0						8											
							1x 58, 3x 118, 4x 999																
Sample B1		4,32	0,58	14	8	CVP	4,32	0,44	24%	3,28	5,36	8	8	100%								0	

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(83) Primidone	[mg/L]				8							8	8	100%							0		
Samples and groups																							
Sample B1		4,32	0,58	14	8	CVP	4,32	0,44	24%	3,28	5,36	8	8	100%							0		
Other					8	0						8											
						1x 58, 3x 118, 4x 999																	
(82) Theophylline	[mg/L]				84																84	82	98%
Samples and groups																							
Sample A1		22,6	1,8	7,8	84							0		CRV	22,58	0,23	24%	17,1	28	84	82	98%	
(1) Abbott		21,2	1,4	6,7	28	0															28		
(58) Beckman Coulter (AU)		24,5	2,4	9,7	10	0															10		
(60) Roche		22,7	1,2	5,4	31	0															31		
(162) Siemens (Atellica)		23,3	1,5	6,4	5	0															5		
Other					10	0															10		
Sample B1		18,4	1,2	6,7	84							0		CRV	18,39	0,18	24%	13,9	22,9	84	83	99%	
(1) Abbott		17,5	1,0	5,7	28	0															28		
(58) Beckman Coulter (AU)		19,6	1,7	8,7	10	0															10		
(60) Roche		18,8	0,86	4,6	31	0															31		
(162) Siemens (Atellica)		18,9	0,67	3,5	5	0															5		
Other					10	0									3x 12, 3x 29, 1x 149, 1x 166, 2x 179					10			
																							3x 12, 3x 29, 1x 149, 1x 166, 2x 179
Set 2																							
(89) Amicacin	[mg/L]				37							37	36	97%							0		
Samples and groups																							
Sample A2		18,1	0,87	4,8	37	CVP	18,1	0,35	20%	14,4	21,8	37	37	100%							0		
(1) Abbott		18,8	0,44	2,4	6	0						6											
(60) Roche		17,9	0,66	3,7	21	0						21											
Other					10	0						10											
						2x 12, 4x 58, 1x 149, 1x 162, 2x 179																	
Sample B2		29,8	1,3	4,5	37	CVP	29,8	0,54	20%	23,8	35,8	37	36	97%							0		
(1) Abbott		31,3	0,67	2,1	6	0						6											
(60) Roche		29,8	0,87	2,9	21	0						21											
Other					10	0						10											
						2x 12, 4x 58, 1x 149, 1x 162, 2x 179																	
(90) Gentamicin	[mg/L]				68							68	66	97%							0		
Samples and groups																							
Sample A2		7,39	1,6	22	68							68	67	99%							0		
(6) Immunoturbidimetry, KIMS; (60) Roche; (60) Roche		5,30	0,29	5,5	12	0	CVPG	5,3	0,20	21%	4,18	6,42	12										
(1) Abbott		8,18	0,91	11	25	0	CVP	7,88	0,38	31%	5,43	10,4	25										
(58) Beckman Coulter (AU)		8,16	1,0	13	6	0	CVP	7,88	0,38	31%	5,43	10,4	6										
(60) Roche		6,75	0,83	12	13	0	CVP	7,88	0,38	31%	5,43	10,4	13										
Other					12	0						12											
						1x 0, 3x 12, 2x 149, 3x 162, 3x 179																	
Sample B2		3,44	0,58	17	68							68	66	97%							0		
(6) Immunoturbidimetry, KIMS; (60) Roche; (60) Roche		2,52	0,22	8,8	12	0	CVPG	2,52	0,16	21%	1,99	3,05	12										
(1) Abbott		3,72	0,38	10	25	0	CVP	3,64	0,11	31%	2,51	4,77	25										

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability										Traceability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(90) Gentamicin	[mg/L]				68							68	66	97%									0	
Samples and groups																								
Sample B2		3,44	0,58	17	68							68	66	97%									0	
(58) Beckman Coulter (AU)		3,54	0,34	9,6	6	0	CVP	3,64	0,11	31%	2,51	4,77	6											
(60) Roche		3,45	0,29	8,4	13	0	CVP	3,64	0,11	31%	2,51	4,77	13											
Other					12	0							12											
							1x 0, 3x 12, 2x 149, 3x 162, 3x 179																	
(93) Methotrexate	[µmol/L]				11							11	11	100%									0	
Samples and groups																								
Sample A2		3,21	0,33	10	11	CVP	3,21	0,25	30%	2,24	4,18	11	11	100%									0	
(1) Abbott		3,17	0,37	12	10	0							10											
Other					1	0							1											
							1x 179																	
Sample B2		1,10	0,07	6,3	11	CVP	1,1	0,052	30%	0,77	1,43	11	11	100%									0	
(1) Abbott		1,11	0,07	7,0	10	0							10											
Other					1	0							1											
							1x 179																	
(92) Vancomycin	[mg/L]				69							69	68	99%									0	
Samples and groups																								
Sample A2		11,0	0,82	7,5	69	CVP	11	0,24	28%	7,92	14,1	69	68	99%									0	
(1) Abbott		11,4	0,49	4,3	27	0							27											
(58) Beckman Coulter (AU)		9,78	0,67	6,9	6	0							6											
(60) Roche		11,0	0,65	5,9	25	0							25											
Other					11	0							11											
							2x 12, 2x 149, 4x 162, 3x 179																	
Sample B2		15,9	1,2	7,3	69	CVP	15,9	0,34	28%	11,4	20,4	69	68	99%									0	
(1) Abbott		16,5	0,88	5,3	27	0							27											
(58) Beckman Coulter (AU)		14,1	0,56	4,0	6	0							6											
(60) Roche		15,9	0,69	4,3	25	0							25											
Other					11	0							11											
							2x 12, 2x 149, 4x 162, 3x 179																	

st_kn_np

End of report

Printed: 14.10.2022